Skip to main content
U.S. flag

An official website of the United States government

Curcuminoid submicron particle ameliorates cognitive deficits and decreases amyloid pathology in Alzheimer’s disease mouse model

Bibliographic

Year of Publication:
2018
Contact PI Name:
Irene H. Cheng
Contact PI Affiliation:
Institute of Brain Science, National Yang-Ming University, Taipei, Taiwan
Co-Authors:
Yi-Heng Tai, Yu-Yi Lin, Kai-Chen Wang, Chao-Lin Chang, Ru-Yin Chen, Chia-Chu Wu
Primary Reference (PubMED ID):
Funding Source:
Cheng Hsin General Hospital
National Health Research Institutes of Taiwan
Taiwan Ministry of Economic Affairs
Taiwan Ministry of Education
Taiwan Ministry of Science and Technology
Yen Tjing Ling Medical Foundation
Study Goal and Principal Findings:

Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder and is triggered via abnormal accumulation of amyloid-β peptide (Aβ). Aggregated Aβ is responsible for disrupting calcium homeostasis, inducing neuroinflammation, and promoting neurodegeneration. In this study, we generated curcuminoid submicron particle (CSP), which reduce the average size to ~60 nm in diameter. CSP had elevated the bioavailability in vivo and better neuroprotective effect against oligomeric Aβ than un-nanosized curcuminoids in vitro. Two months of CSP consumption reversed spatial memory deficits and the loss of a calcium binding protein calbindin-D28k in the hippocampus of AD mouse model. In addition, CSP consumption lowered amyloid plaques and astrogliosis in vivo and enhanced microglial Aβ phagocytosis in vitro, implying that the beneficial effects of CSP also mediated via modulating neuroinflammation and enhancing amyloid clearance. Taken together, our study demonstrated the protective effects of CSP toward ameliorating the memory impairment and pathological deficits in AD mouse model.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Biologic - Nanoparticle
Therapeutic Agent:
Curcuminoid Submicron Particle (CSP)
Therapeutic Target:
Multi Target

Animal Model

Model Information:
Species:
Mouse
Model Type:
Non-transgenic
Strain/Genetic Background:
ICR
Species:
Mouse
Model Type:
APP
Strain/Genetic Background:
Not Reported
Species:
Rat
Model Type:
Outbred
Strain/Genetic Background:
Not Applicable
Animal Model Notes:
Biosafety tests were performed on Sprague Dawley rats. ICR mice were used for micronucleus assay.

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest
Experiment Notes

Experiments using rats were gender balanced. Experiments with mice were not gender balanced.

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Elevated Plus Maze
Morris Water Maze
Open Field Test
Motor Function
Swimming Speed
Locomotor Activity
Histopathology
Activated Astrocytes
Activated Microglia
beta Amyloid Deposits
beta Amyloid Load
Biochemical
Brain-Guanidine Soluble beta Amyloid Peptide 42
Inducible Nitric Oxide Synthase (iNOS/NOS2)
Interleukin 4 (IL-4)
beta Amyloid Aggregation
Chitinase 3-Like Protein 3 (YM1)
Immunochemistry
Calbindin
Glial Fibrillary Acidic Protein (GFAP)
Ionized Calcium Binding Adaptor Molecule 1 (Iba1)
Cell Biology
beta Amyloid Peptide Clearance
Cell Viability
Microglial Phagocytosis
Pharmacokinetics
Area Under the Curve (AUC)
Cmax
Tmax
Toxicology
Body Weight
Micronucleus Formation
Mortality
Organ Weight
Water Consumption